APPENDICES. A systematic review and economic model of the ...

Study Intervention Participants Outcomes
Core symptoms
Not reported
Reference
Barkley et al., 1990 39
Co-existent problems
Not reported
Source
AHRQ Report
Educational performance
Not reported
Arm 1
MPH
0.3 mg/kg/dose; administered twice
daily (a.m. and noon)
(Individual administering medication
not reported)
Setting
USA
Psychological function
Not reported
Arm 2
MPH
0.5 mg/kg/dose; administered twice
daily (a.m. and noon)
(Individual administering medication
not reported)
Design
Crossover trial
Depression or anxiety
Not reported
Inclusion criteria
1. IQ > 80 (Peabody Picture Vocabulary)
2. Parental and/or teacher complaints of significant problems
with inattention, overactivity and impulsivity
3. Placement at the 93rd percentile on the hyperactivity scales
using the Child Behaviour Checklist
4. Appearance of symptoms before age 7 years
5. Symptoms persisting for at least 12 months
6. No gross sensory or motor disabilities, epilepsy, autism,
psychosis, tic disorders or Tourette syndrome, or significant
cardiac problems
Diagnostic criteria
See inclusion criteria
Duration
Treatment periods:
7–10 days
Quality of life
Not reported
Adverse events
Stimulant Drug Side Effects Questionnaire:
17-item list
Number
Total randomised = 83 (male = 71)
Total withdrawals = 3
Arm 3
Placebo
(Individual administering medication
not reported)
Additional outcomes
Not reported
Reasons for withdrawals:
3 children were unable to complete the drug protocol owing to
serious adverse reactions.
Purpose
To assess the frequency
and severity of sideeffects
associated with
two therapeutic doses
of MPH in children with
ADHD
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Age
8.2 years (mean), 5–13 years (range), 2.2 years (SD)
Health Technology Assessment 2006; Vol. 10: No. 23
IQ
105.1 (mean)
Co-morbid disorders
Not reported
Diagnostic subtypes
Not reported
Additional information
No relevant information reported
213